Impact of autologous dendritic cell-based immunotherapy (AGS-004) on B- and T-cell subset changes and immune activation in HIV-infected patients receiving antiretroviral therapy

J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):345-50. doi: 10.1097/QAI.0b013e3182a4b9ad.

Abstract

We previously reported that a combination of antiretroviral therapy with 4 monthly injections of each patient's own autologous dendritic cells (AGS-004) electroporated with CD40 ligand and with HIV RNA antigens obtained from each patient's own pre-antiretroviral therapy plasma induced HIV-specific CD8 T-cell responses in 10 patients. To assess other AGS-004-induced immune changes, we evaluated the modifications in B- and T-cell subsets and the level of immune activation in these patients. The proportion of Bm1 naive cells was increased along with an augmentation of the proliferation marker Ki67. Memory B-cell frequency, CD4 and CD8 T-cell subsets, regulatory T-cell frequency, and CD38/HLA-DR/PD-1 T-cell activation levels remained unchanged after AGS-004 dendritic cell immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B-Lymphocyte Subsets / physiology*
  • CD4 Lymphocyte Count
  • Dendritic Cells / physiology*
  • HIV Infections / immunology
  • HIV Infections / therapy*
  • Humans
  • Immunotherapy / methods*
  • RNA, Viral
  • T-Lymphocyte Subsets / physiology*
  • Viral Load
  • Virus Replication

Substances

  • RNA, Viral